SpliSense secures $28.5 million in funding to advance mRNA-altering pipeline for treatment of CF

Retrieved on: 2021-05-13 19:07:30

Tags for this article:

Click the tags to see associated articles and topics

SpliSense secures $28.5 million in funding to advance mRNA-altering pipeline for treatment of CF. View article details on hiswai:

Excerpt

Jerusalem-based biopharmaceutical company SpliSense, which is developing transformative mRNA-altering therapies for cystic fibrosis (CF) and ...

Article found on: www.calcalistech.com